FENNEC PHARMACEUTICALS INC. Quarterly Operating Income (Loss) in USD from Q2 2010 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Fennec Pharmaceuticals Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q2 2010 to Q2 2024.
  • Fennec Pharmaceuticals Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$5.04M, a 7.99% decline year-over-year.
  • Fennec Pharmaceuticals Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was $5.87M.
  • Fennec Pharmaceuticals Inc. annual Operating Income (Loss) for 2023 was -$12.8M, a 43.5% increase from 2022.
  • Fennec Pharmaceuticals Inc. annual Operating Income (Loss) for 2022 was -$22.6M, a 31.2% decline from 2021.
  • Fennec Pharmaceuticals Inc. annual Operating Income (Loss) for 2021 was -$17.2M, a 3.7% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $5.87M -$5.04M -$373K -7.99% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q1 2024 $6.24M $13.7M +$19M Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 -$12.8M -$1.82M +$4.32M +70.4% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-29
Q3 2023 -$17.1M -$1.02M +$6.88M +87.1% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 -$24M -$4.67M +$343K +6.85% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 -$24.3M -$5.27M -$1.72M -48.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 -$22.6M -$6.14M -$1.93M -45.8% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-29
Q3 2022 -$20.7M -$7.9M -$3.73M -89.3% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$16.9M -$5.01M -$1.09M -27.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-07
Q1 2022 -$15.8M -$3.55M +$1.38M +28% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-12
Q4 2021 -$17.2M -$4.21M -$861K -25.7% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-29
Q3 2021 -$16.4M -$4.17M +$1.69M +28.8% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$18M -$3.92M +$925K +19.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-12
Q1 2021 -$19M -$4.92M -$1.09M -28.4% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 -$17.9M -$3.35M +$307K +8.4% Oct 1, 2020 Dec 31, 2020 10-K 2022-02-28
Q3 2020 -$18.2M -$5.86M -$4M -214% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$14.2M -$4.85M -$32K -0.67% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-10
Q1 2020 -$14.2M -$3.84M -$1.16M -43.1% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q4 2019 -$13M -$3.65M -$548K -17.6% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-30
Q3 2019 -$12.5M -$1.86M +$985K +34.6% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-16
Q2 2019 -$13.4M -$4.81M -$2.15M -80.6% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 -$11.3M -$2.68M -$889K -49.6% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-14
Q4 2018 -$10.4M -$3.11M -$590K -23.5% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-14
Q3 2018 -$9.82M -$2.85M -$662K -30.3% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 -$9.16M -$2.67M -$1.19M -80.2% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-09
Q1 2018 -$7.97M -$1.79M -$1.02M -132% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-10
Q4 2017 -$6.95M -$2.52M -$1.37M -119% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-15
Q3 2017 -$5.58M -$2.19M -$1.62M -288% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-13
Q2 2017 -$3.96M -$1.48M -$772K -109% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-13
Q1 2017 -$3.19M -$771K -$317K -69.8% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-14
Q4 2016 -$2.87M -$1.15M -$595K -108% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-28
Q3 2016 -$2.28M -$564K -$226K -66.9% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-13
Q2 2016 -$2.05M -$707K -$158K -28.8% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-14
Q1 2016 -$1.89M -$454K -$2K -0.44% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-12
Q4 2015 -$1.89M -$551K +$240K +30.3% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-29
Q3 2015 -$2.13M -$338K +$281K +45.4% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-14
Q2 2015 -$2.41M -$549K +$381K +41% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-12
Q1 2015 -$2.79M -$452K +$85K +15.8% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-12
Q4 2014 -$2.88M -$791K -$375K -90.1% Oct 1, 2014 Dec 31, 2014 10-K 2016-03-28
Q3 2014 -$2.5M -$619K -$568K -1114% Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-12
Q2 2014 -$1.93M -$930K -$3K -0.32% Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-11
Q1 2014 -$1.93M -$537K $0 0% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-15
Q4 2013 -$1.93M -$416K +$708K +63% Oct 1, 2013 Dec 31, 2013 10-K 2015-03-31
Q3 2013 -$2.64M -$51K +$579K +91.9% Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-13
Q2 2013 -$3.22M -$927K +$323K +25.8% Apr 1, 2013 Jun 30, 2013 10-Q 2014-08-11
Q1 2013 -$3.54M -$537K +$79K +12.8% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-15
Q4 2012 -$3.62M -$1.12M -$223K -24.8% Oct 1, 2012 Dec 31, 2012 10-K 2014-03-31
Q3 2012 -$3.4M -$630K +$314K +33.3% Jul 1, 2012 Sep 30, 2012 10-Q 2013-11-18
Q2 2012 -$3.71M -$1.25M -$678K -119% Apr 1, 2012 Jun 30, 2012 10-Q 2013-08-09
Q1 2012 -$3.03M -$616K +$405K +39.7% Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-13
Q4 2011 -$3.44M -$901K Oct 1, 2011 Dec 31, 2011 10-K 2013-04-01
Q3 2011 -$944K -$27K -2.94% Jul 1, 2011 Sep 30, 2011 10-Q 2012-11-14
Q2 2011 -$572K +$1.93M +77.2% Apr 1, 2011 Jun 30, 2011 10-Q 2012-08-13
Q1 2011 -$1.02M Jan 1, 2011 Mar 31, 2011 10-Q 2012-05-15
Q3 2010 -$917K Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-14
Q2 2010 -$2.51M Apr 1, 2010 Jun 30, 2010 10-Q 2011-08-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.